Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Transfusions Clear all
Completed Not applicable Interventional

Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction

NCT00816127
View directory record Official record
Conditions
Liver Cirrhosis, Coagulopathy
Interventions
Desmopressin, blood transfusion
Drug · Biological
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2008 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational Results available

Transfusions and Nitric Oxide Level in Preterm Infants

NCT00787124
View directory record Official record
Conditions
Prematurity, Anemia, Necrotizing Enterocolitis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Up to 365 Days
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Jul 21, 2026, 6:54 AM EDT
Recruiting Phase 2 Interventional

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

NCT04143724
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
ACE-536
Drug
Lead sponsor
Celgene
Industry
Eligibility
6 Years to 17 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 6:54 AM EDT
Withdrawn Not applicable Interventional

Blood Conservation in Cardiac Surgery

NCT01463345
View directory record Official record
Conditions
Transfusion Reactions, Post Cardiac Surgery
Interventions
Blood transfusion
Other
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Jul 21, 2026, 6:54 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs

NCT00319657
View directory record Official record
Conditions
Immune Tolerance
Interventions
Hematopoietic cell transplantation, Total lymphoid irradiation
Biological · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Jul 21, 2026, 6:54 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

NCT05356195
View directory record Official record
Conditions
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Interventions
CTX001
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational

Transfusion Using Stored Whole Blood

NCT02926274
View directory record Official record
Conditions
Trauma, Hemorrhage, Coagulopathy
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Jul 21, 2026, 6:54 AM EDT
No Longer Available No phase listed Expanded access

Compassionate Use of Stanate (TM) [Stannsoporfin]

NCT00076960
View directory record Official record
Conditions
Neonatal Jaundice, Hyperbilirubinemia
Interventions
Stanate (TM) [stannsoporfin, tin-mesoporphyrin]
Drug
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Industry
Eligibility
12 Hours to 1 Week
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Pappalysin 2 (PAPP-A2) Enzyme Replacement

NCT02412943
View directory record Official record
Conditions
Short Stature, Idiopathic
Interventions
Fresh Frozen Plasma
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

NCT02125877
View directory record Official record
Conditions
Chronic Iron Overload Due to Transfusion-dependant Anemias
Interventions
Deferasirox dispersible tablet, Defearisox film-coated tablet
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Orange, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Early Phase 1 Interventional Results available

RHD Genotype Matched Red Cells for Anti-D

NCT04156906
View directory record Official record
Conditions
Sickle Cell Disease, Anti-D Antibodies
Interventions
D+ RH genotype matched red cell units for transfusion
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Jul 21, 2026, 6:54 AM EDT
Not yet recruiting Not applicable Interventional

The Efficacy of the KARL STORZ Curved Fetoscope and Straight Fetoscope for Laser Photocoagulation of Placental Anastomoses

NCT06084247
View directory record Official record
Conditions
Twin to Twin Transfusion Syndrome
Interventions
Curved KARL STORZ fetoscope, Conventional Scopes
Device
Lead sponsor
Jimmy Espinoza
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational

Comparison of Pulse Hemoglobin and Pleth Variability Index

NCT01602978
View directory record Official record
Conditions
Anemia, Fluid Management
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Jul 21, 2026, 6:54 AM EDT
Recruiting Phase 1Phase 2 Interventional

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

NCT03653338
View directory record Official record
Conditions
Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia
Interventions
CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab, Fludarabine, Thiotepa
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

NCT03802916
View directory record Official record
Conditions
Iron Overload Due to Repeated Red Blood Cell Transfusions
Interventions
Deferiprone DR tablets 1000 mg (Low dosage), Deferiprone DR tablets 1000 mg (High dosage)
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jul 21, 2026, 6:54 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones

NCT00556400
View directory record Official record
Conditions
Aplastic Anemia, Menorrhagia, Amenorrhea
Interventions
Lo-Ovral Oral Contraceptive Pills, Placebo - sugar pill
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 55 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational

Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients

NCT05255445
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Pediatric Cancer
Interventions
Red Blood Cell (RBC) Transfusion
Biological
Lead sponsor
Westat
Other
Eligibility
Not listed
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Oakland, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 2 Interventional

Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus

NCT00133367
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Myelogenous Leukemia, Lymphoblastic Leukemia
Interventions
Tacrolimus, Sirolimus, G-CSF, Antithymocyte globulin, Thymoglobulin, Fludarabine, Melphalan
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational

ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

NCT00466063
View directory record Official record
Conditions
Anemia
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 5 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)

NCT02280655
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Storage-aged red blood cells (saRBCs) units, Fresh red blood cells units
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Not applicable Interventional

High Yield Intraoperative, Autologous Platelet Apheresis

NCT01819246
View directory record Official record
Conditions
Allogenic Transfusion of Platelets During Cardiac Surgery
Interventions
Aphersis Treatment Arm, Control Arm
Procedure · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Jul 21, 2026, 6:54 AM EDT
Not listed Not applicable Interventional

Effects of Tranexamic Acid on Blood Loss and Transfusion Requirement Following Hip Fracture

NCT02738073
View directory record Official record
Conditions
Hip Fracture
Interventions
Control: Saline, Tranexamic Acid
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jul 21, 2026, 6:54 AM EDT
Not yet recruiting Phase 4 Interventional

Sucrosomial Vs Intravenous Iron for Preoperative Anemia

NCT07287371
View directory record Official record
Conditions
Anemia, Iron Deficiency Anemia
Interventions
Treatment with oral sucrosomial iron, Treatment with intravenous iron
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 21, 2026, 6:54 AM EDT
Withdrawn Not applicable Interventional

Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease

NCT00459225
View directory record Official record
Conditions
Anemia
Interventions
Iron (ferrous sulfate)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 2 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Jul 21, 2026, 6:54 AM EDT